CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

What Happened? A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed ...

If you're confident that its current trials will prove successful, then this is one to buy and sit on. One word of caution ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

The upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of -$2.99 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $127.17 ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

The two companies collaborated on research showing quantum computing could greatly aid the design of mRNA-based medicines and ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...